BIOA BioAge Labs, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1709941 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY45.3%
TTM net income YoY-42.2%
TTM EPS YoY-118.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,401.8%
Net margin-1,253.6%
FCF margin-1,197.8%
EBITDA margin—
Returns
ROE-34.6%
ROA-32.0%
ROIC (approx.)-52.9%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets5.8%
Debt / equity0.00x
Current ratio15.51x
Interest coverage-913.20x
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-1.6%
Payout ratio—
Capex / revenue5.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $8.99M | $0 | — |
| R&D expense | $73.97M | $59.04M | $33.89M |
| SG&A expense | $27.81M | $19.16M | $14.51M |
| Operating income | -$92.78M | -$78.19M | -$48.40M |
| Interest expense | $697,000 | $2.37M | $7.79M |
| Pretax income | -$80.61M | -$71.11M | -$63.85M |
| Income tax | $0 | $0 | $0 |
| Net income | -$80.61M | -$71.11M | -$63.85M |
| EBITDA | -$92.58M | -$77.99M | -$48.20M |
| EPS (basic) | -2.24 | -6.63 | -38.17 |
| EPS (diluted) | -2.24 | -6.63 | -38.17 |
| Weighted avg. shares (diluted) | 35.93M | 10.73M | 1.67M |
| Balance sheet | |||
| Cash & equivalents | $188.89M | $354.35M | $21.64M |
| Short-term investments | $92.21M | $0 | — |
| Receivables | $769,000 | $0 | — |
| Current assets | $286.79M | $357.10M | $25.31M |
| PP&E, net | $963,000 | $591,000 | $323,000 |
| Total assets | $294.89M | $358.23M | $25.92M |
| Current liabilities | $20.14M | $27.77M | $58.17M |
| Short-term debt | $2.65M | $6.00M | $6.00M |
| Long-term debt | $0 | $2.50M | $8.20M |
| Total debt | $2.65M | $8.50M | $14.20M |
| Total liabilities | $22.84M | $35.11M | $66.60M |
| Shareholders' equity | $272.05M | $323.13M | -$173.40M |
| Net debt | -$186.24M | -$345.85M | -$7.44M |
| Shares outstanding | 37.39M | 35.85M | 1.67M |
| Cash flow statement | |||
| Operating cash flow | -$81.63M | -$51.52M | -$37.36M |
| Capital expenditure | $719,000 | $366,000 | $166,000 |
| Free cash flow | -$82.35M | -$51.89M | -$37.53M |
| Investing cash flow | -$95.22M | -$366,000 | -$266,000 |
| Financing cash flow | $11.47M | $381.20M | $34.94M |
| Depreciation & amortization | $200,000 | $200,000 | $200,000 |
| Stock-based compensation | $11.69M | $6.98M | $3.02M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.